L
Luigi Tornillo
Researcher at University Hospital of Basel
Publications - 154
Citations - 10068
Luigi Tornillo is an academic researcher from University Hospital of Basel. The author has contributed to research in topics: Tissue microarray & Cancer. The author has an hindex of 57, co-authored 153 publications receiving 9048 citations. Previous affiliations of Luigi Tornillo include Tongji University & McGill University.
Papers
More filters
Journal ArticleDOI
PD-1 and PD-L1 expression in molecularly selected non-small-cell lung cancer patients.
Armida D'Incecco,M. Andreozzi,Vienna Ludovini,Elisa Rossi,Alessandra Capodanno,Lorenza Landi,Carmelo Tibaldi,Gabriele Minuti,Jessica Salvini,E. Coppi,Antonio Chella,Gabriella Fontanini,Maria Elena Filice,Luigi Tornillo,R. M. Incensati,S. Sani,L. Crinò,Luigi Terracciano,Federico Cappuzzo +18 more
TL;DR: PD-1 and PD-L1 are differentially expressed in oncogene-addicted NSCLC supporting further investigation of specific checkpoint inhibitors in combination with targeted therapies.
Journal ArticleDOI
Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients
Luca Quagliata,Matthias S. Matter,Salvatore Piscuoglio,Salvatore Piscuoglio,Leila Arabi,Christian Ruiz,Alfredo Procino,Michal Kovac,Francesca Moretti,Zuzanna Makowska,Tujana Boldanova,Jesper B. Andersen,Monika Hämmerle,Luigi Tornillo,Markus H. Heim,Sven Diederichs,Clemente Cillo,Luigi Terracciano +17 more
TL;DR: It is demonstrated that the levels of HOTTIP and HOXA13 are associated with HCC patients' clinical progression and predict disease outcome, and novel insights on the function of lncRNA‐driven hepatocarcinogenesis are provided.
Journal ArticleDOI
Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis.
Luca Di Tommaso,Giada Franchi,Young Nyun Park,Barbara Fiamengo,Annarita Destro,Emanuela Morenghi,Marco Montorsi,Guido Torzilli,M. A. Tommasini,Luigi Terracciano,Luigi Tornillo,Raffaella Vecchione,Massimo Roncalli +12 more
TL;DR: The adopted panel of 3 markers is very helpful in distinguishing eHCC‐G1 from dysplastic nodules arising in cirrhosis.
Journal ArticleDOI
Clinical impact of programmed cell death ligand 1 expression in colorectal cancer.
Raoul A. Droeser,Raoul A. Droeser,Christian Hirt,Christian Hirt,Carsten T. Viehl,Daniel M. Frey,Christian A. Nebiker,Christian A. Nebiker,Xaver Huber,Inti Zlobec,Serenella Eppenberger-Castori,Alexander Tzankov,Raffaele Rosso,Markus Zuber,Manuele G. Muraro,Francesca Amicarella,Eleonora Cremonesi,Michael Heberer,Giandomenica Iezzi,Alessandro Lugli,Luigi Terracciano,Giuseppe Sconocchia,Daniel Oertli,Giulio C. Spagnoli,Luigi Tornillo +24 more
TL;DR: Interestingly, programmed death receptor ligand 1 (PDL-1) and interferon (IFN)-γ gene expression, as detected by quantitative reverse transcriptase polymerase chain reaction (RT-PCR) in fresh frozen CRC specimens were found to be significantly associated with improved survival in MMR-proficient CRC.
Journal ArticleDOI
Frequent high-level expression of the immunotherapeutic target Ep-CAM in colon, stomach, prostate and lung cancers.
Philip Went,M Vasei,Lukas Bubendorf,Luigi Terracciano,Luigi Tornillo,Ursus-Nikolaus Riede,Juha Kononen,Ronald Simon,Guido Sauter,P A Baeuerle +9 more
TL;DR: The data strongly support the notion that Ep-CAM is a prime target for immunotherapies in major human malignancies because the most common human cancers show a low frequency of Ep- CAM-negative tumours, a high frequency of epithelial cell adhesion molecule expression on cells of a given tumour, and for most cancers, an insignificant influence of tumour staging, grading and histology.